| Literature DB >> 29693779 |
Hirohito Kubota1, Katsutsugu Umeda1, Kouzuki Kagehiro1, Kuniaki Tanaka1, Tomoo Daifu1, Takayuki Hamabata1, Seishiro Nodomi1, Itaru Kato1, Hidefumi Hiramatsu1, Yoshiki Arakawa2, Takashi Mizowaki3, Souichi Adachi4.
Abstract
The clinical outcome of high-dose chemotherapy (HDC) with autologous stem cell transplantation was retrospectively analyzed in six patients with recurrent intracranial germinoma. Prior to HDC, all patients achieved complete remission after platinum and ifosfamide-based chemotherapy. A melphalan-based conditioning regimen was administered in either a single cycle or multiple sequential cycles. Five of the six patients are alive and free from disease, with a median survival of 65 months, among which four patients avoided re-irradiation. In a significant proportion of patients, recurrent intracranial germinoma is curable by HDC without re-irradiation, provided that the disease remains sensitive to salvage chemotherapy.Entities:
Keywords: high-dose chemotherapy; intracranial germinoma; melphalan; re-irradiation; recurrence
Mesh:
Year: 2018 PMID: 29693779 DOI: 10.1002/pbc.27104
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167